Mizuho upgraded Sarepta (SRPT) to Outperform from Neutral with a price target of $26, up from $19. The firm has greater confidence in the adoption of Elevidys following the company’s Q3 report. Strong demand drove outperformance in Q3 despite the commercial pause and heightened safety concerns, the analyst tells investors in a research note. Mizuho says Sarepta’s commentary points to continued favorable coverage. It sees a favorable risk/reward at current share levels.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta Therapeutics’ Earnings Call: Revenue Resilience Amid Challenges
- Mixed Financial Signals and Future Revenue Concerns Lead to Hold Rating for Sarepta Therapeutics
- Sarepta Stock’s (SRPT) Painful Plunge! Is There Any Hope Left for Investors after DMD Trial Miss?
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV
- Sarepta falls -33.5%